FindTrial
Sign In

Role of inflammatory mediators RAGE, sRAGE for developing atherosclerosis in patients with Diabetes Mellitus

The role of receptor for advanced glycation end products (RAGE’s) and soluble RAGE (sRAGE) in Coronary Artery Disease patients with Diabetes Mellitus - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/08/072105
Enrollment
160
Registered
2024-08-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I259- Chronic ischemic heart disease, unspecified

Interventions

Control Intervention1: NIL: NIL

Sponsors

GB Pant Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with confirmed cases of Atherosclerosis with Coronary Angiography with more than 50% stenosis in atleast one vessel

Exclusion criteria

Exclusion criteria: Patients with Acute Coronary Syndrome such as Myocardial Infarction and Patients with Cardiac diseases such as Valvular diseases and Cardiomyopathy

Design outcomes

Primary

MeasureTime frame
Serum levels of RAGE and sRAGE in Coronary artery disease patients with and without diabetes mellitusTimepoint: 1 YEAR—

Secondary

MeasureTime frame
RAGE gene expression and its correlation with blood levels of RAGE and sRAGE and patient phenotype in above patient groupsTimepoint: 1 year—

Countries

India

Contacts

Public ContactDr Mohit Singh

GB Pant Hospital, GIPMER

pradeep.dabla@gmail.com9718592467

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026